Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination Patients With Thalassemic and Falcemic Syndromes (HEMOGLOB-VAX)
Monitoring of Anti-SARS-CoV-2 (COVID 19) and Encapsulated Vaccination in a Cohort of Patients With Thalassemic and Falcemic Syndromes
Sponsor: Società Italiana Talassemie ed Emoglobinopatie
A observational or N/A phase clinical study on SARS-CoV-2 Infection, Thalasemmie, SCD, this trial is ongoing. The trial is conducted by Società Italiana Talassemie ed Emoglobinopatie and has accumulated 6 data snapshots since 2022. Infectious disease trials contribute critical data for public health response and treatment development.
Status Flow
Change History
6 versions recorded-
Sep 2025 — Present [monthly]
Active Not Recruiting
-
Sep 2024 — Sep 2025 [monthly]
Active Not Recruiting
-
Jul 2024 — Sep 2024 [monthly]
Active Not Recruiting
-
May 2023 — Jul 2024 [monthly]
Active Not Recruiting
Status: Recruiting → Active Not Recruiting
-
Mar 2022 — May 2023 [monthly]
Recruiting
▶ Show 1 earlier version
-
Jan 2022 — Mar 2022 [monthly]
Recruiting
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Società Italiana Talassemie ed Emoglobinopatie
For direct contact, visit the study record on ClinicalTrials.gov .